including stroke, heart failure, and even death. Yet, the current standard of care — including antiarrhythmic drugs and blind, anatomical-based ablation therapy — is suboptimal and is associated with severe side effects and disappointingly low success rates.¹
There is a critical need for a safe and more effective ECG-based arrhythmia mapping system.
Vektor Medical, Inc. aims to revolutionize arrhythmia therapy with vMap™, a next generation, non-invasive system. Using the standard 12-lead ECG, vMap™ has been designed to provide physicians with actionable information by visualizing potential arrhythmia hotspots in all four chambers of the heart.
